about
Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitorsIg gene-like molecule CD31 plays a nonredundant role in the regulation of T-cell immunity and toleranceGadd45beta deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling.Linking JNK signaling to NF-kappaB: a key to survival.Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity.NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respirationIn the Crosshairs: NF-κB Targets the JNK Signaling Cascade.Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways.The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity.Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophagesCancer: NF-κB regulates energy metabolism.Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.NF-kappaB-dependent regulation of the timing of activation-induced cell death of T lymphocytes.Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling.Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors.Growth arrest and DNA damage protein 45b (Gadd45b) protects retinal ganglion cells from injuries.GADD45β loss ablates innate immunosuppression in cancer.NF-κB in the crosshairs: Rethinking an old riddle.Probing the interaction interface of the GADD45β/MKK7 and MKK7/DTP3 complexes by chemical cross-linking mass spectrometry.Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.Gadd45 beta forms a homodimeric complex that binds tightly to MKK7.Turning an old GADDget into a troublemaker.Insights into the Structural Basis of the GADD45β-mediated Inactivation of the JNK Kinase, MKK7/JNKK2Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myelomaNF-κB and mitochondria cross paths in cancer: mitochondrial metabolism and beyond
P50
Q24305602-CC83F5F5-5633-43D7-A333-71D266F88ECFQ24602902-6FC7B7EF-7CBD-448A-8999-9175674A6193Q33805657-F6B4398E-843A-4BE2-8187-F56EC32A333BQ34358664-16AC09DA-B658-4020-8C9E-B35E0D4E8B2FQ35720003-9E3C24EA-B1D1-4CFD-AF84-A79D27822F43Q36291524-CAA25C19-9E6B-422C-A3CA-B3DFAEE75AB2Q37385176-192AFFD5-7FB3-4BE0-BB63-F171A37D439DQ37417042-8073096A-C50A-4A56-9815-C637E5DF56FFQ37433941-7CD71AD1-0681-47F9-A502-CF275153CE36Q37528466-258CF81E-C963-4129-ADD3-E2CE603E6F17Q38035708-98FB8C88-1B03-4B68-9968-31E6335580B6Q39264005-36054226-8B88-42C0-9E82-8DAFC823FC7DQ40321218-DBD08450-3358-479C-85D7-7F0FDFEEE45CQ42158504-7C6D25D7-7FE7-4D91-8DA1-AAF4C7F089DBQ42370929-D35BBDDF-AF80-4806-AA2C-3B3916741898Q43154293-43CF1969-BE4B-43BF-92ED-BC51435CA9FBQ49568351-A3D30D0D-3B9E-48B2-A4EC-6F12DDA065A8Q49578499-BF587495-D89F-45CF-B4CE-BE69D36B868AQ52344076-5E353F29-358C-4CE5-B193-431C6387749CQ52538370-DE8A1D36-5778-47C9-891D-2F53ABE95B9EQ53491878-C271BC53-530B-4A44-9826-D7C156431A3CQ55177549-A87F2996-375A-4A41-95E0-4260F9E21B38Q58419536-426DA056-6513-492C-A0AA-9A437ECE4D99Q64101441-5F8B4C7E-1477-44ED-BBB6-FDF6EAE4C0A6Q91749606-89C7D6E0-FECF-481A-B8C8-83AFD95EEA83Q92317230-49D1FC74-03E2-4D12-B278-237D5A8D169E
P50
description
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Guido Franzoso
@ast
Guido Franzoso
@en
Guido Franzoso
@en-gb
Guido Franzoso
@es
Guido Franzoso
@nl
Guido Franzoso
@sl
type
label
Guido Franzoso
@ast
Guido Franzoso
@en
Guido Franzoso
@en-gb
Guido Franzoso
@es
Guido Franzoso
@nl
Guido Franzoso
@sl
prefLabel
Guido Franzoso
@ast
Guido Franzoso
@en
Guido Franzoso
@en-gb
Guido Franzoso
@es
Guido Franzoso
@nl
Guido Franzoso
@sl
P106
P31
P496
0000-0002-0778-988X